Heather M. Moore

1.3k total citations
41 papers, 842 citations indexed

About

Heather M. Moore is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Heather M. Moore has authored 41 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 11 papers in Genetics. Recurrent topics in Heather M. Moore's work include Advanced Breast Cancer Therapies (18 papers), Cancer Treatment and Pharmacology (13 papers) and HER2/EGFR in Cancer Research (13 papers). Heather M. Moore is often cited by papers focused on Advanced Breast Cancer Therapies (18 papers), Cancer Treatment and Pharmacology (13 papers) and HER2/EGFR in Cancer Research (13 papers). Heather M. Moore collaborates with scholars based in United States, Spain and Switzerland. Heather M. Moore's co-authors include Celina G. Kleer, Maria E. González, Kathy A. Toy, Jodi Thrasher, Sara E. Martin, Christopher D. Baker, Michael S. Sabel, Wei Huang, Kelley M. Kidwell and Xin Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Heather M. Moore

38 papers receiving 823 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heather M. Moore United States 13 334 294 212 136 136 41 842
Woo‐Kyun Bae South Korea 16 190 0.6× 184 0.6× 194 0.9× 70 0.5× 75 0.6× 38 627
Michelle Moghadassi United States 18 158 0.5× 210 0.7× 200 0.9× 116 0.9× 119 0.9× 31 1.0k
Margaret Childs United Kingdom 17 174 0.5× 443 1.5× 603 2.8× 25 0.2× 280 2.1× 34 1.9k
Hyun‐Jeong Shim South Korea 19 227 0.7× 202 0.7× 329 1.6× 50 0.4× 72 0.5× 50 824
Corrado Terranova Italy 23 107 0.3× 199 0.7× 239 1.1× 70 0.5× 132 1.0× 74 1.4k
Margaret Wesley United States 12 160 0.5× 58 0.2× 450 2.1× 56 0.4× 90 0.7× 19 983
Annelies Janssens Belgium 18 333 1.0× 119 0.4× 360 1.7× 40 0.3× 55 0.4× 62 767
Isabella C. Glitza United States 19 319 1.0× 255 0.9× 579 2.7× 114 0.8× 49 0.4× 46 953
Xiaobo Zhong United States 15 61 0.2× 172 0.6× 214 1.0× 76 0.6× 82 0.6× 59 706
Stella Capriglione Italy 24 92 0.3× 205 0.7× 223 1.1× 122 0.9× 151 1.1× 66 1.6k

Countries citing papers authored by Heather M. Moore

Since Specialization
Citations

This map shows the geographic impact of Heather M. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather M. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather M. Moore more than expected).

Fields of papers citing papers by Heather M. Moore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather M. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather M. Moore. The network helps show where Heather M. Moore may publish in the future.

Co-authorship network of co-authors of Heather M. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Heather M. Moore. A scholar is included among the top collaborators of Heather M. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather M. Moore. Heather M. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yao, Xiaosai, Patrick Aouad, Lisa Crocker, et al.. (2025). ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nature Cancer. 6(2). 357–371. 3 indexed citations
2.
Anders, Carey K., et al.. (2025). Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer. Breast Cancer Research and Treatment. 214(3). 329–337. 1 indexed citations
3.
Chibly, Alejandro, Pablo Ernesto Pérez, Heather M. Moore, et al.. (2024). CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. npj Breast Cancer. 10(1). 15–15. 10 indexed citations
4.
5.
Malhi, Vikram, et al.. (2024). UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer Chemotherapy and Pharmacology. 94(1). 117–122. 1 indexed citations
6.
Chandarlapaty, Sarat, Maura N. Dickler, José Alejandro Pérez Fidalgo, et al.. (2023). An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 29(15). 2781–2790. 7 indexed citations
7.
8.
Ingalla, Ellen, Xiaosai Yao, Jennifer M. Giltnane, et al.. (2022). Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Science Translational Medicine. 14(663). eabo5959–eabo5959. 9 indexed citations
9.
Bardia, Aditya, Ingrid A. Mayer, Eric P. Winer, et al.. (2022). The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 197(2). 319–331. 14 indexed citations
10.
Moore, Heather M., et al.. (2022). Comprehensive In-Patient Education Consult for Asthma Exacerbations. Respiratory Care. 67(6). 682–687. 4 indexed citations
11.
Dent, Susan, et al.. (2022). How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer. JACC CardioOncology. 4(3). 404–408. 6 indexed citations
12.
Dent, Susan, et al.. (2021). Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current Oncology Reports. 23(11). 128–128. 33 indexed citations
13.
14.
Moore, Heather M., Heidi Savage, Carol O’Brien, et al.. (2019). Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics. 19(1). 292–303. 8 indexed citations
15.
Abramson, Vandana G., Mafalda Oliveira, Andrés Cervantes, et al.. (2019). A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Research and Treatment. 178(1). 121–133. 4 indexed citations
16.
Moore, Heather M., et al.. (2016). Ultrasonography in the preoperative difficult airway assessment. Journal of Clinical Monitoring and Computing. 31(3). 513–530. 49 indexed citations
17.
Savage, Heidi, Carol O’Brien, Heather M. Moore, et al.. (2016). Abstract 372: Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines. Cancer Research. 76(14_Supplement). 372–372. 1 indexed citations
18.
Moore, Heather M.. (2013). The Role of EZH2 in Breast Cancer Progression and Metastasis.. Deep Blue (University of Michigan). 2 indexed citations
19.
Moore, Heather M., Maria E. González, Kathy A. Toy, et al.. (2013). EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Research and Treatment. 138(3). 741–752. 41 indexed citations
20.
Smith, Dirk E., Roberta Hanna, Della Friend, et al.. (2003). The Soluble Form of IL-1 Receptor Accessory Protein Enhances the Ability of Soluble Type II IL-1 Receptor to Inhibit IL-1 Action. Immunity. 18(1). 87–96. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Woo‐Kyun Bae Breakdown of academic impact, for papers by Michelle Moghadassi Breakdown of academic impact, for papers by Margaret Childs Breakdown of academic impact, for papers by Hyun‐Jeong Shim Breakdown of academic impact, for papers by Corrado Terranova Breakdown of academic impact, for papers by Margaret Wesley Breakdown of academic impact, for papers by Annelies Janssens Breakdown of academic impact, for papers by Isabella C. Glitza Breakdown of academic impact, for papers by Xiaobo Zhong Breakdown of academic impact, for papers by Stella Capriglione
Rankless by CCL
2026